Ondansetron

Early intrauterine death (< 22 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S2778
R4604		 Fejzo (Mainly exposed to other treatements, sick), 2016 Miscarriages (1-12 and 13-20 weeks) 1st trimester retrospective cohort exposed to other treatment, sick excluded Adjustment: No 0.13 [0.10;0.18] C
excluded (control group) 		64/1,070   250/771 314 1,070
ref
S2776
R4605		 Fejzo (Unexposed control, disease free), 2016 Miscarriages (1-12 and 13-20 weeks) 1st trimester retrospective cohort unexposed, disease free Adjustment: No 0.42 [0.31;0.56] C 64/1,070   205/1,555 269 1,070
ref
S2746
R4608		 Pasternak, 2013 Spontaneous abortion (7-22 weeks) early pregnancy population based cohort retrospective unexposed (general population or NOS) Adjustment: No 0.39 [0.27;0.56] C 32/1,849   322/7,396 354 1,849
ref
S2755
R3667		 Einarson (Control exposed to other antiemetics), 2004 Miscarriage (NOS) 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 0.37 [0.13;1.05] C
excluded (control group) 		5/176   13/176 18 176
ref
S2754
R3663		 Einarson (Unexposed control), 2004 Miscarriage (NOS) 1st trimester prospective cohort unexposed, disease free Adjustment: No 0.34 [0.12;0.96] C 5/176   14/176 19 176
ref
Total 3 studies 0.40 [0.32;0.50] 642 3,095
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Fejzo (Unexposed control, disease free), 2016Fejzo, 2016 1 0.42[0.31; 0.56]2691,07058%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Pasternak, 2013Pasternak, 2013 0.39[0.27; 0.56]3541,84937%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Einarson (Unexposed control), 2004Einarson, 2004 2 0.34[0.12; 0.96]191765%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 0% 0.40[0.32; 0.50]6423,0950.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Unexposed control, disease free; 2: Unexposed control;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.40[0.32; 0.50]6423,0950%NAFejzo (Unexposed control, disease free), 2016 Pasternak, 2013 Einarson (Unexposed control), 2004 3 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 0.40[0.32; 0.50]6423,0950%NAFejzo (Unexposed control, disease free), 2016 Pasternak, 2013 Einarson (Unexposed control), 2004 3 Tags Adjustment   - No  - No 0.40[0.32; 0.50]6423,0950%NAFejzo (Unexposed control, disease free), 2016 Pasternak, 2013 Einarson (Unexposed control), 2004 3 All studiesAll studies 0.40[0.32; 0.50]6423,0950%NAFejzo (Unexposed control, disease free), 2016 Pasternak, 2013 Einarson (Unexposed control), 2004 30.110.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 2755, 2778

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) Out of scale0.40[0.32; 0.50]6423,0950%NAFejzo (Unexposed control, disease free), 2016 Pasternak, 2013 Einarson (Unexposed control), 2004 3 exposed to other treatment, sick controlsexposed to other treatment, sick controls Out of scale0.19[0.07; 0.51]3321,24670%NAFejzo (Mainly exposed to other treatements, sick), 2016 Einarson (Control exposed to other antiemetics), 2004 20.510.01.0